We are live on ! Find out more
CLYM

Climb Bio
CLYM

35 hedge funds and large institutions have $182M invested in Climb Bio in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

9% more funds holding

Funds holding: 32 → 35 (+3)

0.4% more ownership

Funds ownership: 65.08% → 65.48% (+0.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

41% less capital invested

Capital invested by funds: $311M → $182M (-$129M)

Holders
35
Holders Change
+3
Holders Change %
+9.38%
% of All Funds
0.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
14
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.59M
2
PPA
Parametric Portfolio Associates
Washington
+$704K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$578K
4
PL
Parkwood LLC
Ohio
+$456K
5
BlackRock
BlackRock
New York
+$363K

Top Sellers

Rank Fund Capital Flow
1
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$1.37M
2
Millennium Management
Millennium Management
New York
-$1.29M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$268K
4
HF
HRT Financial
New York
-$212K
5
WP
Woodline Partners
California
-$207K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$138M – – –
SC
2
Samlyn Capital
New York
$17.8M +$336K +22,521 +1%
WP
3
Woodline Partners
California
$3.9M -$207K -13,856 -4%
BlackRock
4
BlackRock
New York
$3.73M +$363K +24,318 +7%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.2M +$1.59M +106,761 +53%
MIM
6
Monashee Investment Management
Massachusetts
$3.14M -$78K -5,233 -2%
JP Morgan Chase
7
JP Morgan Chase
New York
$2.18M +$68.4K +4,590 +2%
Tudor Investment Corp
8
Tudor Investment Corp
Connecticut
$2.04M -$1.37M -91,836 -32%
Goldman Sachs
9
Goldman Sachs
New York
$1.72M -$27.3K -1,829 -1%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.21M +$578K +38,768 +50%
Hudson Bay Capital Management
11
Hudson Bay Capital Management
Connecticut
$1.05M – – –
State Street
12
State Street
Massachusetts
$974K +$104K +6,978 +8%
CCM
13
CAAS Capital Management
New York
$785K – – –
Northern Trust
14
Northern Trust
Illinois
$641K -$11K -741 -1%
PPA
15
Parametric Portfolio Associates
Washington
$494K +$704K +47,191 New
PL
16
Parkwood LLC
Ohio
$320K +$456K +30,609 New
Charles Schwab
17
Charles Schwab
California
$181K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$147K +$12.6K +847 +6%
OWP
19
Old Well Partners
North Carolina
$108K +$154K +10,300 New
Morgan Stanley
20
Morgan Stanley
New York
$106K +$59.8K +4,009 +66%
CPIG
21
Chicago Partners Investment Group
Illinois
$100K +$186K +12,486 New
Wells Fargo
22
Wells Fargo
California
$67K +$95.3K +6,393 +20,623%
UBS Group
23
UBS Group
Switzerland
$47K -$141K -9,435 -68%
Deutsche Bank
24
Deutsche Bank
Germany
$45K +$3.43K +230 +6%
Bank of America
25
Bank of America
North Carolina
$45K +$54.9K +3,685 +600%
1
2

CLYM Hedge Fund Activity: Q4 2021 in Review

35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q4 2021, worth a combined $182M — down 41% from $311M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CLYM positions and 3 closed out — a net gain of 3 holders — while 14 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was Tudor Investment Corp, cutting an estimated $1.37M.

  • 35 institutional investors held Climb Bio (CLYM) as of Q4 2021, up from 32 in Q3 2021.
  • Funds reported $182M of Climb Bio stock for Q4 2021, down 41% quarter-over-quarter.
  • 6 funds opened new Climb Bio positions in Q4 2021 and 3 closed out, a net change of +3 holders.
  • The largest Climb Bio buyer in Q4 2021 was Vanguard Group, an estimated $1.59M added.
  • The largest Climb Bio seller in Q4 2021 was Tudor Investment Corp, an estimated $1.37M sold.

Based on aggregated 13F filings for Q4 2021.